Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer

Clinical Colorectal Cancer

Volumn 3, Issue 3, 2003, Pages 147-149

  Klem, Jennifer ^a   Chu, Edward ^a   Jain, Vinay K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ARTICLE; ATAXIA; CANCER INVASION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; FATIGUE; HUMAN; HYPERTENSION; METASTASIS; NEUTROPENIA; NONHUMAN; THROMBOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION; VEIN OCCLUSION; VOMITING;

EID: 0348230600     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70081-0     Document Type: Article

References (15)

1. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409-416.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
3. Dazzi C, Cariello A, Maioli P, et al. Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. Lung Cancer 1999; 24:81-88.
4. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541-546.
5. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
6. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothetial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996; 93:14765-14770.
7. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
8. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
9. DeVore R, Fehrenbacher L, Herbst R, et al. A randomized phase II trial comparing rHuMab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19: (Abstract #1896).
10. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003. Available at: http://www.asco.org/hurwitz_no3646. Accessed November 11, 2003. Abstract #3646.
11. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60:4819-4824.
12. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-3964.
13. Trarbach T, Thomas AL, Bartel C, et al. Preliminary phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer. Eur J Cancer 2003; 1(suppl 5):S91 (Abstract #297).
14. Clinicaltrials.gov. National Institutes of Health. First line treatment of metastatic colorectal cancer with oxaliplatin/5-FU/leucovorin plus PTK787/ZK 222584 or placebo. Available at: http://www.clinicaltrials.gov/ct/show/NCT00056459?order=1. Accessed November 11, 2003.
15. Clinicaltrials.gov. National Institutes of tealth. Treatment of patients with previously reated metastatic colorectal cancer with oxaliplatin/5FU/LV and PTK787 or placebo. Available at: http://www.clinicaltrials.gov/ct/show/NCT00056446?order=1. Accessed November 11, 2003.